The National Institute for Health and Care Excellence for England and Wales (NICE), has reversed an earlier negative decision and...
Novartis announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra (ofatumumab) plus...
The European Commission (EC) has granted marketing authorisation for a new indication for the use of Arzerra (ofatumumab), from Glaxo...
GSK announced an agreement with Novartis Pharma AG, a subsidiary of Novartis AG, to divest its rights in Arzerra (ofatumumab)...
The FDA has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra (ofatumumab), from Glaxo Smith Kline/Genmab,...
GlaxoSmithKline plc and Genmab A/S announced that the Phase III study (ORCHARRD) of ofatumumab (Arzerra) plus chemotherapy versus rituximab plus...
GlaxoSmithKline and Genmab have announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a Phase III study, PROLONG...
Phase III data published in The Lancet showed that treatment with Arzerra (ofatumumab), from Novartis, plus chlorambucil, a chemotherapy, resulted...
Glaxo Smith Kline and Genmab have submitted a variation to the Marketing Authorisation to the European Medicines Agency for the...
Genmab announces it is removing Arzerra from the chronic lymphocytic leukaemia market outside the US.